SEC Company Response from SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478) (SLS) — Jul 25, 2018
SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478)
Date: July 25, 2018 · CIK: 0001390478 · Accession: 0001193125-18-225863
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226251
Letter
July 25, 2018
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Ada D. Sarmento
Office of Healthcare & Insurance
Re:
SELLAS Life Sciences Group, Inc.
Registration Statement on Form S-3
Filed July 19, 2018
File No. 333-226251
Acceleration Request
Requested Date: Thursday, July 26, 2018
Requested Time: 4:30 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, SELLAS Life Sciences Group, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-226251) to become effective on July 26, 2018, at 4:30 P.M., Eastern Time, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes each of Yvan-Claude Pierre and Marianne Sarrazin of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
In connection with this request, the Registrant acknowledges that:
•
should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
SELLAS Life Sciences Group, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP July 25, 2018 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ada D. Sarmento Office of Healthcare & Insurance Re: SELLAS Life Sciences Group, Inc. Registration Statement on Form S-3 Filed July 19, 2018 File No. 333-226251 Acceleration Request Requested Date: Thursday, July 26, 2018 Requested Time: 4:30 P.M. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, SELLAS Life Sciences Group, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-226251) to become effective on July 26, 2018, at 4:30 P.M., Eastern Time, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes each of Yvan-Claude Pierre and Marianne Sarrazin of Cooley LLP, counsel to the Registrant, to make such request on its behalf. In connection with this request, the Registrant acknowledges that: • should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and 1 • the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Very truly yours, SELLAS Life Sciences Group, Inc. By: /s/ Angelos M. Stergiou Angelos M. Stergiou, MD, ScD h.c. President and Chief Executive Officer cc: Gene Mack, SELLAS Life Sciences Group, Inc. Barbara A. Wood, SELLAS Life Sciences Group, Inc. Yvan-Claude Pierre, Cooley LLP Marianne Sarrazin, Cooley LLP 2